High density lipoprotein mediates anti-inflammatory transcriptional reprogramming of macrophages via the transcriptional repressor ATF3 by De Nardo, Dominic et al.
 
High density lipoprotein mediates anti-inflammatory transcriptional
reprogramming of macrophages via the transcriptional repressor
ATF3
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation De Nardo, D., L. I. Labzin, H. Kono, R. Seki, S. V. Schmidt, M.
Beyer, D. Xu, et al. 2014. “High density lipoprotein mediates anti-
inflammatory transcriptional reprogramming of macrophages via
the transcriptional repressor ATF3.” Nature immunology 15 (2):
152-160. doi:10.1038/ni.2784. http://dx.doi.org/10.1038/ni.2784.
Published Version doi:10.1038/ni.2784
Accessed February 16, 2015 9:11:06 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12785919
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAHigh density lipoprotein mediates anti-inflammatory
transcriptional reprogramming of macrophages via the
transcriptional repressor ATF3
Dominic De Nardo1,*, Larisa I. Labzin1,*, Hajime Kono2, Reiko Seki2, Susanne V. Schmidt3,
Marc Beyer3, Dakang Xu4,5, Sebastian Zimmer6, Catharina Lahrmann6, Frank A.
Schildberg7, Johanna Vogelhuber1, Michael Kraut3, Thomas Ulas3, Anja Kerksiek8,
Wolfgang Krebs3, Niklas Bode6, Alena Grebe1, Michael L. Fitzgerald9, Nicholas J.
Hernandez9, Bryan Williams4, Percy Knolle7, Manfred Kneilling10,11, Martin Röcken10,
Dieter Lütjohann8, Samuel D. Wright12, Joachim L. Schultze3,*, and Eicke Latz1,13,14,*
1Institute of Innate Immunity, University Hospitals, Biomedical Centre, University of Bonn,
Germany
2Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
3Life and Medical Sciences Institute (LIMES), University of Bonn, Germany
4Monash Institute of Medical Research, Monash University, Melbourne, Victoria, Australia
5Institute of Ageing Research, Hangzhou Normal University School of Medicine, Hangzhou,
China
6Department of Medicine/Cardiology, University of Bonn, Germany
7Institutes of Molecular Medicine and Experimental Immunology, University of Bonn, Germany
8Instititute for Clinical Chemistry and Clinical Pharmacology, University of Bonn, Germany
9Lipid Metabolism Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA
10Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
11Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy,
Eberhard Karls University, Tuebingen, Germany
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research,
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding author: Eicke Latz, MD, PhD, Institute of Innate Immunity, University of Bonn, Sigmund-Freud-Str. 25, 53127 Bonn,
Germany, Phone: +49 228 287 51223, Fax: +49 228 287 51221, eicke.latz@uni-bonn.de.
*These authors contributed equally to this work.
ACCESSION NUMBERS
All microarray data of this study where uploaded onto Gene Expression Omnibus (GEO) and can be accessed under GSE44034.
AUTHOR CONTRIBUTIONS
D.D, L.I.L, H.K, R.S, designed and performed experiments and analyzed data, S.V.S, D.X. F.A.S, J.V, A.K, M.Kr, N.B, A.G, C.L,
S.Z, N.H performed experiments, S.V.S, M.B, T.U, W.K, and J.L.S, analyzed transcriptome and ChIP sequencing data, M.Kn. and
M.R. provided the Atf3-deficient and matched WT control mice, D.L, M.L.F, B.W, P.K and S.D.W analyzed data and provided critical
suggestions and discussions throughout the study, D.D, L.I.L, J.L.S and E.L. designed the study and along with S.D.W. wrote the
paper.
COMPETING FINANCIAL INTERESTS
S.D.W is a paid employee of CSL Behring.
NIH Public Access
Author Manuscript
Nat Immunol. Author manuscript; available in PMC 2014 August 01.
Published in final edited form as:
Nat Immunol. 2014 February ; 15(2): 152–160. doi:10.1038/ni.2784.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t12Cardiovascular Therapeutics, CSL Limited, Parkville, Australia
13Division of Infectious Diseases and Immunology, University of Massachusetts Medical School,
Worcester, USA
14German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Abstract
High Density Lipoprotein (HDL) mediates reverse cholesterol transport and it is known to be
protective against atherosclerosis. In addition, HDL has potent anti-inflammatory properties that
may be critical for protection against other inflammatory diseases. The molecular mechanisms of
how HDL can modulate inflammation, particularly in immune cells such as macrophages, remain
poorly understood. Here we identify the transcriptional repressor ATF3, as an HDL-inducible
target gene in macrophages that down-regulates the expression of Toll-like receptor (TLR)-
induced pro-inflammatory cytokines. The protective effects of HDL against TLR-induced
inflammation were fully dependent on ATF3 in vitro and in vivo. Our findings may explain the
broad anti-inflammatory and metabolic actions of HDL and provide the basis for predicting the
success of novel HDL-based therapies.
The innate immune system utilizes several families of signaling receptors to detect invading
pathogens or tissue damage1. While an appropriate inflammatory response is critical for
clearing pathogens and maintaining tissue integrity, excessive or prolonged inflammation
can lead to harmful systemic inflammation and organ dysfunction. However, multiple
regulatory mechanisms have evolved to limit the extent and duration of the inflammatory
response. For instance, while Toll-like receptor (TLR) activation leads to the expression of
pro-inflammatory cytokines it also induces the expression of many negative regulators,
acting to limit signal transduction, mRNA transcription or translation2. Of these, Activating
Transcription Factor 3 (ATF3) is a key inducible transcriptional repressor, which binds to
specific CREB-ATF elements within the promoter loci of specific target genes resulting in
chromatin remodeling and subsequent inhibition of transcription factor binding3. ATF3 is
induced by TLR stimulation as well as a multitude of other stimuli4 and acts in a negative
feedback system to limit excessive production of pro-inflammatory cytokines including
TNF, IL-6 and IL-12p403, 5. Understanding how these regulatory pathways work in the
context of chronic inflammatory disease is of great interest and may lead to the design of
beneficial therapeutics.
Atherosclerosis is the chronic inflammatory condition underlying coronary artery disease
and is driven in part via the recognition of metabolic danger signals by innate immune
receptors on macrophages6, 7. Elevated levels of HDL cholesterol are associated with
reduced atherothrombotic events8. Furthermore, animal studies have shown HDL to be
beneficial on the key cell types and processes in atherosclerosis, in part by mediating the
removal of cholesterol from lipid-laden macrophages (known as foam cells)9. However,
therapies based on simply increasing HDL cholesterol levels have been largely
unsuccessful10,11, prompting the suggestion that the functionality of HDL may be more
important to disease outcome than the quantity of HDL itself12. Indeed, cholesterol efflux
capacity is better correlated with disease risk than total HDL cholesterol levels13. HDL also
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thas anti-oxidant, anti-thrombotic and anti-inflammatory properties, which may also protect
against atherogenesis14–16. The anti-inflammatory nature of HDL could also be beneficial in
other inflammatory diseases: it can lower endothelial cell vascular cell adhesion molecule 1
(VCAM1) expression, increase endothelial nitric oxide synthase (eNOS) production and
reduce monocyte CD11b expression and migration along an monocyte chemotactic
protein-1 (MCP-1) gradient17. However, the molecular mechanisms by which HDL
mediates its anti-inflammatory functions, especially in macrophages and outside of the
context of atherosclerosis, remain poorly understood.
We therefore investigated the effects of HDL on macrophage activation by TLRs and in
macrophage-dependent models of inflammation under normo-cholesterolemic conditions.
Here we show that HDL inhibits TLR-induced production of pro-inflammatory cytokines
from macrophages. These effects were independent of HDL binding TLR ligands and did
not involve modulation of TLR signaling events, or disruption of cytokine secretory
processes. Rather, in a time-dependent manner, HDL suppressed the ability of TLRs to
induce the expression of pro-inflammatory cytokines (such as IL-6, IL-12p40 and TNF) on
the transcriptional level. Using a systems biology approach we identified ATF3 as an HDL-
inducible negative regulator of macrophage activation. Transcriptome analysis revealed that
HDL regulated many genes in an ATF3-dependent manner, and ATF3 ChIP sequencing
confirmed that several key pro-inflammatory genes were directly targeted by ATF3
following its induction by HDL. Furthermore, the ability of HDL to reduce TLR responses
was found to be fully dependent on ATF3 expression both in vitro and in vivo,
demonstrating the critical role of this transcriptional repressor in the anti-inflammatory
effects of HDL.
RESULTS
HDL is protective against TLR-induced inflammation
HDL has multiple functions beyond promoting the efflux of cholesterol from lipid-laden
cells. To study the anti-inflammatory effects of HDL under normo-cholesterolemic
conditions, we utilized a well-established in vivo model of acute inflammation, in which the
systemic release of pro-inflammatory cytokines from TLR activated macrophages leads to
liver damage18, 19. Mice were injected with HDL freshly isolated from patients (native
HDL) or with purified human Apolipoprotein A1 (ApoAI; the major protein component of
HDL) reconstituted with phospholipids (referred to hereafter as HDL) and subsequently
challenged with TLR agonists. Pre-treatment with either native HDL or HDL significantly
reduced liver damage induced by the TLR9 activator CpG-DNA (CpG), as measured by
alanine aminotransferase (ALT) release (Fig. 1a,b) or hepatocyte cell death (Fig. 1c and data
not shown). In addition, mice injected with CpG following pre-treatment with native HDL
displayed significantly reduced serum levels of the pro-inflammatory cytokines IL-6 and
IL-12p40 (Fig. 1a). Similarly, mice pre-treated with HDL showed reduced serum
concentrations of CpG-induced IL-6, IL-12p40, TNF, MCP-1 and IL-10 (Fig. 1b), whereas
IL-18 and IL-13 remained unaffected (Supplementary Fig. 1a). In addition, HDL pre-
treatment significantly reduced liver damage and inflammation mediated by the TLR1-2
ligand, Pam3CysK4 (P3C) (Fig. 1d). We further investigated the anti-inflammatory effect of
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tHDL in vitro using bone marrow-derived macrophages (BMDMs). Pre-treatment of
BMDMs with HDL substantially reduced IL-6, IL-12p40 and TNF cytokine output in
response to a variety of TLR ligands (Fig. 1e), without impacting cell viability (Fig. 1f).
HDL reduced TLR-mediated cytokine production in a dose-dependent manner
(Supplementary Fig. 1b). Comparable decreases in TLR-induced IL-6 production were also
observed following pre-treatment of BMDMs with native HDL (Fig. 1g). HDL’s ability to
decrease TLR-induced inflammation was also evident in human peripheral blood
mononuclear cells (PBMCs) (Supplementary Fig. 1c). Collectively, these data suggest HDL
is protective against TLR-induced inflammation by down modulating the production of pro-
inflammatory cytokines from monocytes and macrophages.
HDL regulates inflammation at the transcriptional level
HDL can directly neutralize the inflammatory activity of LPS20–22. To examine whether
HDL neutralizes other TLR activators by direct interaction, we analyzed if HDL can change
the size exclusion profile of fluorescent TLR agonists. As expected, HDL led to a shift of
LPS fluorescence into the higher molecular weight HDL fractions (Fig. 2a), demonstrating
LPS binding to HDL. In contrast, HDL did not change the elution profile of fluorescent CpG
or P3C (Fig. 2a and data not shown), indicating that HDL does not directly interact with
these TLR ligands. Furthermore, direct binding by HDL should abolish or reduce the ability
of TLR ligands to activate their downstream signaling pathways. Consistent with our size
exclusion data, HDL did not block CpG- or P3C-induced p38 mitogen-activated protein
kinase (MAPK) phosphorylation (p-p38) in BMDMs, indicating successful interaction of the
ligands with their receptors (Fig. 2b). In contrast, HDL co-treatment abolished LPS induced
p38 activation (Fig. 2b). These data suggest that while HDL can attenuate LPS-induced
inflammation by sequestration, they do not explain the anti-inflammatory effects of HDL on
other TLR ligands, including CpG and P3C.
HDL promotes the efflux of cholesterol from macrophages and thus, subsequent TLR
activation might be inhibited via changes to lipid raft cholesterol content23, 24. However,
while pre-treatment of BMDMs with HDL decreased cellular cholesterol concentration (Fig.
2c and Supplementary Fig. 2a), it did not inhibit CpG-induced signaling, including
activation of p38 MAPK, JNK, NF-κB p65, or the degradation of IκBα (Fig. 2d).
Furthermore, HDL pre-treatment had no effect on the nuclear translocation of NF-κB (Fig.
2e), nor did it prevent NF-κB binding to target DNA sequences (Fig. 2f). Together these
data exclude the possibility of interference with early TLR signaling mechanisms. To assess
whether HDL affects cytokine secretion, we measured cytokines in intracellular
compartments. Although HDL pre-treatment had no effect on the activation of NF-κB p65
in response to TLR stimulation, intracellular cytokine expression was diminished in HDL
pre-treated BMDMs (Fig. 2g), as was the amount of secreted cytokines (Fig. 2h and
Supplementary Fig. 2b,c). These data suggest that HDL interferes with cytokine production
but not its secretion. Consistent with this hypothesis, relative mRNA expression of pro-
inflammatory cytokines was notably reduced when BMDMs were treated with HDL or
native HDL prior to CpG stimulation (Fig. 2i and Supplementary Fig. 2d). Cytokine mRNA
expression was also decreased in the livers of mice injected with HDL or native HDL prior
to CpG (Fig. 2j and Supplementary Fig. 2e). We next assessed if HDL was affecting the
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thalf-life of TLR-induced cytokine mRNA or protein. HDL pre-treatment of BMDMs did not
alter the stability of IL-6 mRNA transcripts (Supplementary Fig. 2f) nor the stability of
IL-1β protein (Supplementary Fig. 2g). Together these data indicate that HDL may regulate
anti-inflammatory effects in macrophages by down modulating pro-inflammatory gene
transcription.
ATF3 is identified as a candidate transcription factor
We noted that macrophages exposed to HDL for longer periods of time displayed a more
pronounced reduction in cytokine production (Fig. 3a), which persisted up to 24 h after
removal of HDL (Fig. 3b). This suggested that the underlying molecular mechanism might
involve de novo transcription of an inflammatory repressor. We therefore used genome-wide
RNA profiling to assess whether HDL affected the transcriptional response to TLR
stimulation, by comparing resting BMDMs with HDL pre-treated BMDMs subsequently
stimulated with CpG. Principle component analysis and hierarchical clustering indicated that
HDL induced significant transcriptional changes in resting and CpG-treated BMDMs
(Supplementary Fig. 3a,b). As expected, HDL treatment alone induced the gene expression
of several enzymes involved in the cholesterol biosynthesis pathway (Supplementary Fig.
3c). This finding correlated with an increased appearance of cholesterol precursors
following HDL treatment as identified by mass spectrometry (Supplementary Fig. 3d).
Stimulation of BMDMs with CpG resulted in regulation of 1135 genes in total; 419 of which
were not influenced by HDL pre-treatment (Fig. 3c,d). The remaining 716 CpG regulated
genes (Fig. 3c, purple overlap) were also regulated by CpG in the presence of HDL relative
to resting to cells. However, HDL further enhanced or reduced the expression of many of
these genes (Figure 3d, purple). HDL treatment also modulated the expression of 423 genes
(250 induced and 173 repressed) independently of CpG treatment (Fig. 3c,d blue). To
identify a potential transcription factor that might be responsible for the anti-inflammatory
effects of HDL, we interrogated our transcriptome data using several bioinformatics
approaches. Firstly, we performed Gene Ontology Enrichment Analysis (GOEA) using the
genes that were regulated by CpG and further modified by HDL, and visualized this as a
Gene Ontology (GO) – term network (Supplementary Fig. 3e). This analysis identified one
subnet, based on genes down-regulated by HDL (blue edges and nodes), that could be
summarized as ‘innate immune response’-related processes, while another large subnet,
based on genes induced by HDL (red edges and nodes), was linked to cholesterol and lipid
metabolism. However, the most significant enrichment scores were linked to a central dense
subnet best summarized as ‘regulation of metabolic processes’. Based on this pronounced
enrichment of regulatory processes we searched for candidates of transcriptional regulation
in this subnet and identified the transcriptional repressor ATF3 in most of the subnet’s GO-
terms (yellow area underlying the network in Supplementary Fig. 3e). Secondly, using the
transcription factor (TF) catalogue database (TFCat database)25, we identified ATF3 as the
TF with the highest expression levels in the presence of HDL (Fig. 3e). Finally, we
performed TF promoter-binding prediction using the genes most significantly repressed by
HDL as bait (fold change (FC)<-3, p<0.05, false discovery rate (FDR), n=33, (Methods and
Supplementary Fig. 3f). Among the 143 TF candidates potentially binding to these
promoters, only ATF3 (FC 2.3) was up-regulated by HDL. TF module analysis validated
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tthese findings and identified potential ATF3 binding sites in 28 out of 33 input genes
(Methods and Supplementary Table 1). Collectively, these analyses strongly support a
model in which HDL leads to the repression of CpG-induced genes by increasing the
expression of the transcriptional repressor ATF3.
ATF3 binds target gene promoters following HDL induction
Consistent with our transcriptome analysis, BMDMs treated with HDL displayed increased
ATF3 mRNA (Fig. 4a) and protein (Fig. 4b) expression in a time-dependent manner. The
induction of ATF3 mRNA and protein by HDL was further potentiated by subsequent CpG
or P3C stimulation (Fig. 4c,d). Native HDL also induced ATF3 mRNA expression to
comparable levels in BMDMs (Fig. 4e). Additionally, HDL treatment increased ATF3
mRNA and protein in human monocytes (Fig. 4f,g). In vivo, HDL injection increased
hepatic ATF3 mRNA expression in C57BL/6 mice (Fig. 4h), specifically within Kupffer
cells (the resident macrophages of the liver) (Fig. 4i). To analyze whether HDL treatment
would modulate ATF3 binding to target gene promoters, we performed ATF3 ChIP
sequencing (ChIP-Seq) on wild type (WT) and Atf3-deficient BMDMs. We used signals
from Atf3-deficient BMDMs to subtract background non-specific binding of the ATF3
antibody. HDL treatment, either alone or in combination with CpG, dramatically increased
ATF3 binding across the genome, while CpG treatment alone reduced ATF3 binding (Fig.
5a). Global assessment of ATF3 peak localization relative to transcription start sites revealed
that ATF3 was specifically enriched in promoter regions of genes (Fig. 5b). Consistent with
our findings that HDL treatment results in reduced production of pro-inflammatory
cytokines, our ChIP-Seq analysis demonstrated significant ATF3-binding at the promoters
of IL-6, IL-12p40 and TNF in the presence of HDL or HDL+CpG, but not CpG alone (Fig.
5c). No enrichment of ATF3 was seen at the promoters of non-HDL regulated cytokines that
we identified in vivo (Supplementary Fig. 1a) such as, IL-18 and IL-13 (Supplementary Fig.
4a). Together these data demonstrate that following induction by HDL, ATF3 is specifically
enriched at the promoters of cytokines found to be regulated by HDL both in vivo and in
vitro, strongly suggesting that the anti-inflammatory effects of HDL are mediated via this
mechanism.
Functions of HDL are most intimately associated with processes related to atherosclerosis.
Thus, we next examined whether ATF3 was induced following HDL treatment in an animal
model of atherosclerosis. We examined the livers of atherosclerosis-prone Apoe-deficient
mice fed on a high fat diet and observed that HDL-injected mice displayed significantly
greater hepatic ATF3 mRNA expression compared with PBS control mice (Fig 5d).
Induction of ATF3 correlated with a substantial reduction in the levels of the direct ATF3
target genes IL-6, IL-12p40 and cholesterol 25-hydroxylase (Ch25h) (Fig. 5e). Notably,
within the livers of HDL injected Apoe-deficient mice, a significant induction of ATF3
mRNA was observed in Kupffer cells, while hepatocytes showed 10-fold less expression
(Supplementary Fig. 4b). This data demonstrates that in an animal model of atherosclerosis
HDL induces the expression of ATF3 within macrophages, which may act to repress the
expression of inflammatory target genes.
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To further assess the role of ATF3 in mediating the anti-inflammatory effects of HDL we
performed genome-wide transcriptome analysis on WT and Atf3-deficient BMDMs pre-
treated with HDL and subsequently stimulated with CpG or P3C. Using the model presented
in Figure 6a, we observed that ATF3 deficiency affected a large set of TLR-driven, HDL-
modulated genes (n=224, Supplementary Table 2a). Transcripts induced or repressed in WT
BMDMs by CpG or P3C alone (green dots) and counter regulated by HDL pre-treatment
(black dots) were no longer modified in the absence of ATF3 (red dots) (Fig. 6b,
Supplementary Fig. 5a and Supplementary Table 2b–e). We observed substantially
overlapping gene sets whether CpG or P3C stimulation was used (Supplementary Fig. 5b).
Furthermore, GOEA network visualization of TLR-regulated genes demonstrated that
immune response related functions modified by HDL were ATF3-dependent, while lipid
metabolism terms were ATF3-independent (Supplementary Fig. 5c). In fact, the majority of
genes within the cholesterol biosynthesis pathway showed ATF3-independent regulation by
HDL (Supplementary Fig. 5d). Accordingly, we did not detect differential gene expression
between WT and Atf3-deficient BMDMs for Srebf226 or Lxr target genes27 (data not
shown), indicating that ATF3 is not involved in their regulation in response to HDL. Of the
genes we identified to be regulated by HDL and CpG in WT cells but not in Atf3-deficient
cells (n=130), approximately 20 % were confirmed as direct ATF3 target genes (n=27) by
ChIP-Seq, and GO-term analysis of these direct ATF3 targets identified significant
enrichment of genes involved in inflammatory processes (Supplementary Fig. 5e).
To confirm that ATF3 was required for HDL mediated inhibition of TLR-induced cytokine
secretion, we compared the effects of HDL pre-treatment on subsequent TLR responses in
WT and Atf3-deficient BMDMs. As expected, HDL significantly reduced CpG-induced IL-6
and IL-12p40 production from WT BMDMs, but not from Atf3-deficient BMDMs (Fig. 7a).
Additionally, we assessed the relevance of ATF3 induction by HDL in vivo by comparing
WT and Atf3-deficient mice subjected to inflammation and liver injury induced by injection
of CpG. Strikingly, HDL was also no longer protective against CpG-induced liver damage in
Atf3-deficient mice, as observed by comparable ALT release from Atf3-deficient animals
injected with or without HDL (Fig. 7b). Accordingly, unlike WT mice, Atf3-deficient mice
injected with HDL showed no significant reductions in serum concentration of IL-12p40 and
TNF, or in hepatic TNF protein expression in response to CpG (Fig. 7b). These data
demonstrate that repression of pro-inflammatory cytokine responses by HDL both in vitro
and in vivo are mediated by the induction of ATF3.
The protective functions of HDL are best documented in the context of atherosclerosis.
Cardiovascular risk factors including hypertension, toxins from cigarette smoke, high blood
sugar and turbulent blood flow can lead to localized and recurrent endothelial damage, a
process thought to be critical in atherogenesis28. Endothelial damage is followed by an
inflammatory response of macrophages that modulates the rate and extent of re-
endothelialisation29,30. Since HDL is known to accelerate vascular wound healing and re-
endothelialisation31–33, we next assessed whether ATF3 is also critical for HDL’s protective
function in an atherosclerosis relevant model of vascular repair. While HDL effectively
increased the amount of re-endothelialization after carotid artery injury in WT mice, no
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tchange was observed in Atf3-deficient mice (Fig. 7c,d). These data suggest that HDL can
dampen the local inflammation that occurs during vascular injury and that ATF3 thereby
contributes to the vascular repair process. To broadly assess HDL’s effects in the vascular
wall after injury, we performed transcriptional profiling of RNA isolated from the injured
carotid artery segments from WT and Atf3-deficient mice that were injected with HDL or
PBS. Hierarchical clustering of genes and samples showed that the replicate samples within
the four groups clustered as four individual groups (Supplementary Fig. 6a). HDL treatment
strongly modulated genes in WT samples but not Atf3-deficient samples, implying that the
effects of HDL treatment were dependent on the presence of ATF3 (Supplementary Fig. 6a).
We next characterized the genes regulated by HDL and ATF3 in carotid artery samples and
overlapped them with those genes earlier identified as regulated by HDL via ATF3 in
macrophages in vitro (Fig. 6 and Supplementary Fig. 5). We performed GOEA analysis with
these genes and visualized the changes of GO-terms induced by HDL in WT but not ATF3
deficient samples using BINGO networks. Consistent with our in vitro macrophage analysis,
HDL led to an ATF3-dependent reduction of the inflammatory responses in carotid artery
samples (Supplementary Fig. 6b). We validated these approaches using Gene Set
Enrichment Analysis (GSEA) on the macrophage-carotid injury overlapping gene set. GSEA
ranks RNA expression results based on their correlation with the phenotype and significant
enrichment. These analyses revealed a highly significant enrichment of these ATF3 target
gene sets in HDL treated samples from WT mice but not Atf3-deficient mice (Fig. 7e). This
data indicates that HDL’s beneficial effects on carotid artery re-endothelialization are for the
most part driven by ATF3 and the reduction of macrophage inflammation
DISCUSSION
Epidemiological studies have consistently documented that low concentrations of HDL
cholesterol in the blood represent a strong, independent risk factor for cardiovascular
disease. The protective effect of HDL in cardiovascular and possibly other inflammatory
diseases is thought to be the result of several beneficial functions. HDL relieves cells from
excessive amounts of cholesterol, has strong anti-oxidative effects, inhibits platelet
aggregation and exerts several vasoprotective effects34. Most notably, HDL also has the
remarkable ability to modulate the inflammatory response in various cell types. HDL
isolated from healthy individuals or reconstituted from purified ApoA1 and phospholipids is
strongly anti-inflammatory. However, during an acute phase response or in chronic
inflammatory states HDL can be modified to become dysfunctional33.
The mechanisms by which HDL reduces inflammatory responses, particularly in
macrophages, are not well understood. While it is known that HDL can sequester LPS and
thereby prevent cellular activation through TLR4, this mechanism does not explain why
HDL can block a broad spectrum of TLR-mediated inflammatory responses in macrophages.
In contrast to the current understanding that HDL can impair TLR signaling through
interference with raft cholesterol levels, we found that TLR signaling and subsequent
nuclear translocation of the pro-inflammatory transcription factor NF-κB remained
unaffected by HDL. We identified that the induction of ATF3, a key transcriptional
repressor of innate immune response genes, is the main mechanism by which HDL mediates
its anti-inflammatory activities in macrophages. ATF3 can be induced by TLR activation
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tand acts as part of an important negative feedback loop to limit TLR-driven inflammatory
responses in macrophages. Hence, by inducing ATF3, HDL utilizes an ancient regulatory
feedback system and can broadly and directly modify the inflammatory response of
macrophages towards TLR stimulation.
This discovery has broad implications as TLR activation triggers macrophage responses that
contribute to a large number of inflammatory pathologies. For example, targeted deletion of
TLRs or components of their signaling pathways in mice confers protection against
atherosclerosis35–37. Furthermore, TLR-inducible pro-inflammatory cytokines such as IL-6,
IL-12p40 and TNF all contribute to atherosclerosis development38. Of note, ATF3 can also
directly regulate cholesterol metabolism pathways by repressing Ch25h expression, an
enzyme required for 25-hydroxycholesterol mediated foam cell formation. Indeed, mice
deficient in both ATF3 and ApoE have enhanced atherosclerotic lesions, which was
attributed to increased expression of Ch25h39. Consistently, we observed that injection of
HDL in Apoe-deficient mice induced ATF3 expression and reduced the expression of
Ch25h, as well as the pro-inflammatory cytokines, IL-6 and IL-12p40. Hence, HDL appears
to modulate both foam cell formation and inflammation via ATF3, which could contribute to
HDL’s protective nature in atherosclerosis. However, HDL is known to exert other effects
that can beneficially influence atherosclerosis that are likely independent of ATF3. For
example, HDL’s anti-oxidative function can prevent LDL oxidation, which itself contributes
to atherogenesis17. Modulation of cellular cholesterol by HDL may also affect antigen
presentation and the induction of an adaptive immune response16. Furthermore, HDL
reverses hyper-proliferation of hematopoietic stem cell precursors, which can exaggerate
atherosclerosis40. Similarly, HDL affects the activation of platelets which do not have a
nucleus41, and it reduces the integrin-mediated adhesion of leukocytes too quickly to
involve transcription42. Therefore, the contribution of ATF3 to HDL’s protective effects
against atherosclerosis in vivo may be difficult to separate from the rest of its protective
functions.
Our ChIP-Seq analysis in macrophages and RNA profiling studies in macrophages and
injured carotid arteries revealed that HDL regulates an exceptionally broad set of target
genes via ATF3 under normo-cholesterolemic conditions. This could be explained by
ATF3’s ability to recruit co-repressors such as histone deacetylase 1 (HDAC1). HDAC1
recruitment by ATF3 is thought to result in less histone acetylation at target gene promoters,
which is typically associated with a closed chromatin and inactivation of genes3, 39. Thus,
via this mechanism, HDL could influence epigenetic modification of target genes. Indeed,
we observed that ATF3 was constitutively bound across target gene promoters in resting
macrophages, which was lost upon CpG stimulation, consistent with transcriptional
activation of these genes. However, HDL treatment further increased ATF3 binding across
the genome, presumably remodeling chromatin structure to prevent transcriptional activation
of these genes. These results provide a long sought mechanistic link between HDL and its
anti-inflammatory function.
While HDL’s protective role is most well characterized in atherosclerosis, its ability to
broadly modulate TLR responses suggests that HDL may be beneficial in other chronic
inflammatory diseases. Our findings raise the possibility of using HDL-based therapeutics in
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ttreating inflammatory disorders not directly linked to hypercholesterolemia. Furthermore,
our results imply that fine-tuning the negative regulators of inflammation, such as ATF3,
may provide a therapeutic avenue for the treatment of a range of inflammatory pathologies.
METHODS
Reagents
Ultrapure LPS (E. coli 0111:B4), Pam3CK4 (referred to as P3C in the text) and R848 were
from Invivogen. Phosphorothioate backbone modified CpG DNA oligonucleotides (referred
to as CpG in the text) were synthesized by Metabion. Murine TLR9 stimulatory CpG DNA
type B 1826 (5′-TCCATGACGTTCCTGACGTT-3′) and human TLR9 stimulatory CpG
DNA type A 2216 (5′-GGGGGACGATCGTCGGGGGG-3′) were used. Anti-phospho-p65
NF-κB (3033), anti-phospho-p38 MAPK (4511), anti-phospho-SAPK/JNK (4668) and anti-
IκB-α (4814) antibodies were from Cell Signaling Technology. Anti-IL-1β (BAF401) and
anti-IL-6 (BAF406) antibodies were from R & D systems. Anti-ATF3 (C19; sc-188) was
from Santa Cruz and anti-PARP (C2-10; 4338) was from Trevigen. Anti-β-tubulin
(926-42211), anti-α-tubulin (926-42213), anti-β-actin (926-42210) and secondary
antibodies; anti-mouse (926-32212), anti-rabbit (926-32213) and anti-goat (926-3214), were
from LI-COR Biosciences. Bovine Serum Albumin (BSA), Actinomycin-D and
cyclohexamide were purchased from Sigma.
Generation of reconstituted HDL
A reconstituted form of HDL (CSL-111, referred to as HDL in the text) with a protein to
phospholipid ratio of 1:160, was generated as described previously43 and kindly provided by
CSL Behring.
Generation of native HDL from human donors
Native HDL from sera of human donors was purified using a stepwise ultracentrifugation
within a density of 1.063–1.21 g/ml as described previously44. The distribution and
chemical composition of separated lipoproteins in human serum was followed by dialysis
against PBS. Alternatively, native HDL was purchased from Meridian Life Science.
Animal models
TLR-induced inflammation and liver injury mouse model—Eight-week old
C3H/HeJ female mice were injected intraperitoneally (i.p.) with 2 mg of native HDL or 500
μl control filtrate 6 hours before i.p. injection of 20 μg CpG DNA and 10 mg D-
galactosamine (D-gal). C3H/HeJ mice (TLR4 mutant) were used to avoid the effects of
endotoxin carried in native HDL. Six- to eight-week old C57BL/6 female mice were
injected i.p. with 2 mg reconstituted HDL or 100 μl PBS for 6 h before i.p. injection of 20 μg
CpG DNA and 10 mg D-gal. Six- to eight-week old Atf3-deficient mice and matched wild
type (WT) mice were injected i.p. with 2 mg reconstituted HDL or 100 μl PBS for 6 h before
i.p. injection of 30 μg CpG DNA and 10 mg D-gal. Blood was collected 1 h following CpG
DNA/D-gal injection and mice were sacrificed after 10 h. At sacrifice livers were analyzed
by haematoxylin and eosin staining and serum analyzed for aminotransferase (ALT) with
DRI-CHEM4000 from Fujifilm. Cytokines were measured by Bio-Plex assay from BIO-
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tRAD. These animal experiments were performed in accordance with the Teikyo University
animal experiments committee of the Teikyo University School of Medicine and also in
accordance with the animal ethics committee of Monash University.
Atherosclerosis mouse model—Eight-week old Apoe-deficient mice were fed a high
fat diet (1.25% Cholesterol) for 8 weeks. During week 8, mice were injected intravenously
(i.v.) two times with HDL (100 mg/kg) or PBS 4 days apart before the animals were
sacrificed and livers collected for RNA isolation and mRNA analysis by qPCR as described
below. These animal experiments were performed with approval from the Landesamt für
Natur, Umwelt und Verbraucherschutz NRW and in accordance with German animal
protection law.
Carotid injury mouse model—For carotid artery injury approximately 12-week old
male WT and Atf3-deficient mice were anesthetized with i.p. injection of 150 mg/kg
ketaminehydrochloride (Ketanest, Pharmacia) and 0.1 mg/kg xylazinehydrochloride
(Rompun 2%, Bayer). A small incision from the cranial apex of the sternum to just below
the mandible was made. After careful preparation of an approximately 6 mm long segment
proximal of the bifurcation, the common carotid artery was electrically denuded. A 4 mm
long lesion was made by applying two serial 5 second bursts of 2 Watt using 2 mm wide
forceps. The skin was then sutured and the mice allowed to recover in individual cages
before returning to their littermates. Three hours later the mice received a single 200 μl i.v.
injection of 20 mg/kg HDL or PBS. After three days, 50 μl Evan’s blue solution was
injected i.v. and allowed to circulate for 5 min. The mice were then sacrificed and both
common carotid arteries fully excised. The arteries were rinsed in 0.9 % NaCl solution and
the residual connective tissue carefully removed. Images were taken, and the total lesion
area (4 mm) and remaining denuded area (stained blue) measured using AxioVision version
4.5.0 software (Zeiss). The percentage of re-endothelialization was calculated as the
difference of blue stained area compared to the total injured area. These animal experiments
were performed with approval from the Landesamt für Natur, Umwelt und
Verbraucherschutz NRW and in accordance with German animal protection law.
Cells
Bone marrow-derived macrophages (BMDMs) were obtained by culturing bone marrow
cells from 6- to 8-week old WT C57BL/6 mice in DMEM supplemented with 10% fetal calf
serum (FCS), 10 μg/ml Ciprobay-500 and 40 ng/ml M-CSF (R & D Systems). Six days later,
BMDMs were harvested and plated.. Age- and sex-matched WT control mice were used to
derive BMDMs for comparative experiments with Atf3-deficient BMDMs. Immortalized
BMDMs were cultured in DMEM supplemented with 10% FCS and 10 μg/ml Ciprobay-500.
Human peripheral blood mononuclear cells (PBMCs) were purified from whole blood over
Ficoll density gradient (GE Healthcare); erythrocytes were lysed in red cell lysis buffer
(Miltenyi Biotec) and seeded in RPMI supplemented with 10% FCS and 10 μg/ml
Ciprobay-500. Human CD14+ monocytes were isolated from PBMCs using CD14
microbeads (Miltenyi Biotec).
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Livers were perfused via the portal vein with a solution of 0.05% collagenase (Sigma-
Aldrich), then mechanically disrupted, filtered through mesh (300 μm) and centrifuged at
300 rpm for 5 min. The hepatocyte cell pellet and the supernatant containing
nonparenchymal liver cells were separated and washed once with Hank’s Balanced Salt
Solution. Nonparenchymal liver cells were labeled with anti-CD11b antibody-labeled
MACS microbeads and purified using immunomagnetic separation (Miltenyi).
Measurement of secreted cytokine levels by ELISA
Cytokines in cell-culture supernatants were measured by ELISA as per the manufacturer’s
instructions. Murine IL-6, IL-12p40 and TNF, and human IL-6 and TNF ELISA kits were
from R & D Systems; the human IFN-α ELISA kit was from eBiosciences.
Cell viability assay
Cell viability of BMDMs determined using CellTitre-Blue® reagent (Promega) according to
the manufacturer’s instructions.
Fast Performance Liquid Chromatography (FPLC)
Approximately 2 nM of 3′ Alexa-647 labeled CpG DNA 1826 (Eurofins MWG Operon) or
40 μg of Bodipy-FL labeled LPS (Invitrogen), were incubated with either PBS or HDL (600
μg) for 2 h at 37°C. Samples were loaded onto a Superdex-200 size exclusion column (GE
Healthcare) and absorbance was read at 260 nm (RNA/DNA), 280 nm (protein).
Fluorescence absorbance was recorded at 505 nm and 647 nm for LPS and CpG,
respectively.
Quantification of cellular cholesterol
BMDMs were lysed in 2x RIPA buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate) and cholesterol
content was measured using the Amplex® Red Cholesterol Assay Kit (Invitrogen) according
to manufacturer’s instructions.
Cell lysis and immunoblotting
Up to 1.5 × 106 BMDMs or CD14+ human monocytes were lysed on ice for 30 min with 1x
RIPA buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10%
glycerol, 0.1% SDS, 0.5% deoxycholate) supplemented with 0.1 μM PMSF, cOmplete
protease inhibitors and PhosSTOP (Roche Biochemicals). Lysates were clarified by
centrifugation at 13,000 × g for 10 min at 4°C and protein concentration measured by BCA
assay (Pierce). Equal amount of protein per sample were then run on 4–12% pre-cast SDS-
PAGE gels (Novex, Invitrogen) with MES or MOPS buffer (Novex, Invitrogen). Separated
proteins were transferred onto PVDF membranes (Millipore) and blocked in 3% BSA in Tris
Buffered Saline with Tween-20 before overnight incubation with specific primary
antibodies. Membranes were then washed and incubated with the appropriate secondary
antibodies, and immunoreactivity was observed by near-infrared detection (Odyssey, LI-
COR).
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Up to 3 × 106 BMDMs were lysed in cytoplasmic lysis buffer (10 mM HEPES pH 7.4, 1.5
M MgCl2 and 10 mM KCl with 0.1% NP-40) supplemented with 0.1 μM PMSF and
cOmplete protease inhibitors (Roche) before intact nuclei were separated from cytoplasmic
content by centrifugation at 2000 × g for 10 min at 4°C. Supernatants were harvested as the
‘cytoplasmic extract’. Nuclei were washed with cytoplasmic lysis buffer, before being lysed
in nuclear lysis buffer (20 mM HEPES pH 7.8, 420 mM NaCl, 20% glycerol, 0.2 mM
EDTA and 1.5 mM MgCl2) and then centrifuged at >13,000 × g for 15 min at 4°C. The
supernatant was then harvested as the ‘nuclear extract’. Protein content was determined by
BCA assay (Pierce). Protein was then subjected to immunoblotting as described above.
Electromobility Shift Assay (EMSA)
Up to 3 × 106 BMDMs were gently lysed in buffer I (10 mM Tris pH 7.8, 5 mM MgCl2, 10
mM KCl, 1 mM EGTA pH7, 5% Sucrose with DTT, cOmplete protease inhibitors, 0.6%
NP-40) and centrifuged at 2000 × g for 10 min at 4°C. The nuclei were then lysed in buffer
II (20 mM Tris pH7.8, 5 mM MgCl2, 330 mM KCl and 200 μM EGTA pH7, 25% glycerol
with DTT and protease inhibitors), centrifuged at >13,000 × g for 15 min at 4°C. The
supernatant was then used as ‘nuclear extract’. Protein content of the nuclear extract was
determined by BCA assay (Pierce) and 5 μg of nuclear extract was incubated with the
IRDye-700 NF-κB consensus oligonucleotide (LI-COR) with Poly dI:dC, DTT and NP-40
from the Odyssey EMSA buffer kit as per the instructions. Samples were run on a 4% TBE
native polyacrylamide gel and bands observed by near-infrared detection (Odyssey, LI-
COR).
Quantification of sterols by mass spectrometry
Immortalized BMDMs grown in DMEM supplemented with 0.5% FCS and 10 μg/ml
Ciprobay-500 were treated with HDL (2 mg/ml) for up to 6 h. Culture supernatants and cells
were then subjected to Gas chromatography-mass spectrometry-selected ion monitoring
(GC-MS-SIM) to determine cholesterol and cholesterol precursor levels as described
elsewhere45, 46.
RNA isolation and generation of cDNA for analysis by SYBR Green qPCR
Up to 3 × 106 BMDMs, isolated Kupffer cells, hepatocytes or homogenised tissue samples
were lysed and RNA isolated with RNeasy or miRNeasy mini kits according to the
manufacturer’s protocol (Qiagen). Approximately 1 μg of isolated RNA from each sample
was synthesized into cDNA using an oligo dT(18) primer and SuperScript™ III Reverse
Transcriptase (Invitrogen). cDNA abundance was measured by quantitative real time PCR
(qPCR) using the Maxima™ SYBR Green/ROX qPCR Master Mix (Fermentas) on a 7900T
thermocycler (Applied Biosystems). The primer sequences were as follows:
Gene: Forward primer (5′ to 3′): Reverse primer (5′ to 3′):
murine HPRT TGAAGTACTCATTATAGTCAAGGGCA CTGGTGAAAAGGACCTCTCG
De Nardo et al. Page 13
Nat Immunol. Author manuscript; available in PMC 2014 August 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tGene: Forward primer (5′ to 3′): Reverse primer (5′ to 3′):
human HRPT TCAGGCAGTATAATCCAAAGATGGT AGTCTGGCTTATATCCAACACTTCG
murine ATF3 GAGCTGAGATTCGCCATCCA CCGCCTCCTTTTCCTCTCAT
human ATF3 CCAACCATGCCTTGAGGATAA GGCAAGGTGCTGAAAATCCTT
murine IL-6 CCAGAAACCGCTATGAAGTTCC CGGACTTGTGAAGTAGGGAAGG
murine IL-12p40 GGAAGCACGGCAGCAGAATA AACTTGAGGGAGAAGTAGGAATGG
murine IL-1β TTGACGGACCCCAAAAGATG CAGCTTCTCCACAGCCACAA
murine Ch25h TGACCTTCTTCGACGTGCTG AGCCAAAGGGCACAAGTCTG
Murine TNF TATGGCCCAGACCCTCACA GGAGTAGACAAGGTACAACCCATC
Primer specificity was checked by melt curve analysis. Expression of target genes was
normalized to the expression of the housekeeping gene, HPRT. For fold change analysis
data was transformed using the ‘Relative Standard Curve Method and Comparative CT
Method (ΔΔCt)’ as described by Applied Biosystems.
RNA isolation for microarray
Up to 107 cells were lysed in 1 ml of TRIZOL reagent and stored at −80°C until further
RNA isolation. A total of 0.2 ml chloroform was added to 1 ml of TRIZOL. The upper
colorless aqueous phase was transferred into a new tube after centrifugation. RNA was
precipitated by addition of 0.5 ml of isopropyl alcohol with a subsequent washing step in at
least 1 ml of 75% ethanol. The precipitated RNA was dissolved in RNase free water. The
RNA quality was assessed by measuring the ratio of absorbance at 260 nm and 280 nm
using a Nanodrop 2000 Spectrometer (Thermo Scientific), as well as by visualization of the
integrity of the 28S and 18S band on an agarose gel.
Genome-wide transcriptome assessment by microarray
Total RNA was purified using the MinElute Reaction Cleanup Kit (Qiagen) prior to array
based gene expression profiling. By using the TargetAmp™ Nano-g™ Biotin-aRNA
Labeling Kit for the Illumina System (Epicentre), biotin-labeled cRNA was generated. The
biotin-labeled cRNA (1.5 μg) was hybridized to MouseWG-6 v2.0 Beadchips (Illumina) and
scanned on an Illumina iScan system.
Data generation and bioinformatics of microarray data
Processing of raw intensity data was performed by BeadStudio 3.1.1.0 (Illumina). All
experiments performed for this study are listed in Supplementary Table 3. Data were
exported using the Partek report builder and imported as non-normalized data into Partek
Genomics Suite V6.6 (PGS) (Partek). Data were then quantile normalized prior to further
analysis. Differentially expressed (DE) genes between the different conditions, as well as
transcripts with variable expression within the dataset were calculated using two- or three-
way ANOVA models including batch correction. DE genes were defined by a fold change
(FC) greater than 2, and a false discovery rate (FDR)-corrected p-value<0.05 unless stated
otherwise. Principle component analysis (PCA) using all transcripts and default settings in
PGS was utilized for visualization of sample relationships. Similarly, default settings within
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tPGS were used for hierarchical clustering to visualize the sample and transcript relationships
of the 1,000 most variable genes based on FDR-corrected p-values within the dataset. To
link differential gene expression to biological processes involved, gene ontology- (GO-) and
pathway-enrichment analysis were performed in PGS. Furthermore, for visualization of GO-
enrichment, BINGO (http://www.psb.ugent.be/cbd/papers/BINGO/Home.html) combined
with Enrichment Map (http://baderlab.org/Software/EnrichmentMap) were utilized as
plugins implemented in Cytoscape (http://www.cytoscape.org). Heatmaps based on log2-
transformed mean expression values were generated using MayDay (http://www-
ps.informatik.uni-tuebingen.de/mayday/wp/). To identify potential transcriptional regulators,
transcripts differentially expressed between CpG-stimulated BMDMs in the presence or
absence of HDL were filtered using the TFCat database47 and their expression values (log2)
visualized as a gene-ranked heatmap.
To predict genes directly targeted by ATF3 following HDL treatment, gene expression
experiments were also performed in Atf3-deficient BMDMs. This allowed the identification
of genes differentially regulated by HDL in WT but not in Atf3-deficient BMDMs, as
potential direct targets of ATF3 downstream of HDL (see Figure 6a). In this model, genes
were defined as ATF3 targets if they met the following three criteria; 1) TLR-modified
genes being elevated (FC >1.5) or reduced (FC < −1.5) in expression by stimulation with
either CpG or P3C, 2) TLR-modified genes showing reduced differences (up or down
towards control) in the presence of HDL by at least 30%, and 3) these same genes showing a
loss of the HDL effect in Atf3-deficient BMDMs.
Gene Set Enrichment Analysis (GSEA; http://www.broadinstitute.org/gsea/index.jsp) was
used to determine whether the ATF3 target gene set is statistically significantly enriched in
the carotid injury model from HDL treated wild-type mice (Enrichment score: 0.81; p-value
0.0; FDR: 0.0)48.
Transcription factor binding prediction
Transcription factor (TF) binding prediction was performed using the Genomatix software
suite (http://www.genomatix.de) (Supplementary Figure 5b). Briefly, gene symbols of bait
genes (most significantly downregulated genes (FC<-3; FDR.p<0.05) in BMDMs treated
with CpG in the presence of HDL) were uploaded into the Genomatix module
‘Gene2Promoter’ to determine transcripts and promoters of these gene loci. Using standard
settings, promoter sequences were compiled as a new sequencing file and further
interrogated with the Genomatix module ‘common TF sites’ to determine TFs with enriched
binding sites within the promoters of the chosen gene loci. For the 33 genes 108 promoter
models (104 sequences, 70,162 bp) were identified by Genomatix search for common TF
sites in multiple sequences and chosen for further analysis. Nine TF families representing
143 TF candidates revealed TF binding sites in at least 80% of the included promoter
models. TF candidates were interrogated for expression as well as differential expression
using the comparison of the transcriptome data (131/143 TFs covered) derived from
BMDMs treated with CpG either in the presence or absence of HDL. Next, the percentage of
expressed genes within the transcriptome dataset (23/131, 17.5%) was determined. Among
those TFs, ATF3 was the only TF upregulated (FC 2.3) in macrophages stimulated with
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tCpG in the presence of HDL (Figure 3f). As a second approach, TF modules on the 108
promoter models were computed using Genomatix FrameWorker, which is designed to
extract a common framework of elements from a set of TF binding sites. As search criteria,
TF modules containing CREB (containing ATF3) or ETSF (containing PU.1) binding sites
were given. A total of 80 sequences, from 30 gene loci with 51,851 bp were interrogated.
Significantly enriched (p<0.03) module hits (n=27) were identified covering 26/30 genes.
The Genomatix module ‘Model inspector’ was utilized to assess the location of the
generated TF modules. The large majority of hits contained combined CREB-ETFS (69%)
modules, with the ETSF family containing the macrophage lineage TF PU.1 (Sfpi1).
Calculation of the percentage of gene loci covering CREB-ETSF TF modules was
performed in EXCEL.
ATF3 ChIP Sequencing (ChIP-seq)
ChIP for ATF3 was performed using the EZ-Magna ChIP G Kit (Millipore) according to the
manufacturer’s instructions. In brief, three biological replicates of BMDMs from WT and
Atf3-deficient mice were treated with HDL, CpG, HDL then CpG or left untreated. Cells
were then cross-linked with 1% paraformaldehyde, before being lysed and chromatin
sheared by sonication for 30 min with the Covaris S220. Immunoprecipitation was
performed over night at 4°C using 2.5 μg of rabbit polyclonal anti-ATF3 antibody (C-19X,
Santa Cruz). After washing, eluted samples were reverse cross-linked and RNaseA- and
proteinase-K-treated as per the manufacturer’s recommendations. ChIP fragments were
ligated to NEXTflex ChIP-Seq barcode adaptors using the NEXTflex ChIP-Seq Kit (both
BioO Scientific). Adaptor ligated DNA fragments were size selected (150–250 bp), PCR
amplified, further size selected (150–250 bp), pooled, and sequenced on an Illumina
HiSeq-1000 sequencer according to the manufacturer’s instructions.
ChIP-Seq analysis
Reads were aligned to the UCSC mm9 reference mouse genome, using Bowtie 0.12.849.
After ChIP-Seq quality control using HOMER v4.2 (http://biowhat.ucsd.edu/homer)50, reads
of biological replicates were pooled, and peak identification was performed using MACS
1.4.2 with the samples from Atf3-deficient BMDMs set as unspecific background to identify
specific ATF3 binding51. Afterwards, HOMER v4.2 was used to annotate the genomic
location of identified peaks. To generate histograms for the distribution of tag densities,
position-corrected tags in 5 bp windows were normalized using Java-genomics-toolkit
(http://palpant.us/java-genomics-toolkit/) and the Atf3-deficient tags subtracted from the WT
tags. For visualization, only enrichment in WT cells is depicted. Tag coverage of HDL-
specific peaks relative to genomic TSS sites was calculated for WT and Atf3-deficient
BMDMs for all conditions using HOMER v4.2.
Statistics
Data are typically presented as mean values ±S.E.M, where a p value of <0.05 was
considered significant as determined by a two-tailed Student’s t test; or as described in
individual figure legends. Analyses were performed with Excel (Microsoft), Prism
De Nardo et al. Page 16
Nat Immunol. Author manuscript; available in PMC 2014 August 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t(GraphPad Software, Inc.), or for microarray data with Partek Genomics Suite (Partek) using
ANOVA-models.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HDL inhibits TLR-induced cytokine production from macrophages in vivo and in vitro. (a–d) Mice were injected
intraperitoneally (i.p.) with 2 mg HDL for 6 h before i.p. injection of TLR ligand (CpG: 20 μg, P3C 2 μg) and D-galactosamine
(10 mg). Serum cytokines were measured after 1 h and serum alanine aminotransferase (ALT) and liver histology after 10 h. a
C3H/HeJ mice injected with native HDL and CpG: ALT release (n=12) and serum cytokines (CpG n=28, native HDL+CpG n=
27) were measured. b,c C57BL/6 mice injected with HDL and CpG: ALT release (n=9); serum cytokines (CpG n=18, HDL
+CpG n=19) (b), and liver histology by hemotoxylin and eosin staining shows hepatic cell death. (c). d, C57BL/6 injected with
HDL and P3C: ALT release (n=15) and serum cytokines (n=15) were measured. e, ELISA of BMDMs treated with 2 mg/ml
HDL for 6 h followed by overnight stimulation with the TLR4 ligand, LPS (100 ng/ml); TLR9 ligand, CpG (100 nM); TLR7/8
ligand, R848 (5 ng/ml); or TLR2/1 ligand P3C (50 ng/ml). f, Cell viability was measured with CellTitre- Blue® reagent. g,
BMDMs were pre-treated with recombinant or native HDL (2 mg/ml) for 6 h and stimulated overnight with CpG (100 nM) or
P3C (50 ng/ml) and IL-6 cytokine secretion measured by ELISA. a,b,d Data are presented as mean values ±S.E.M, CpG versus
HDLs+CpG *p<0.05, **p<0.01, ***p<0.005, c, images are representative of mice with median ALT concentration; scale bars,
100 μm, e,f,g data is shown as mean ±S.D. and is representative of at least three independent experiments.
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HDL inhibits TLR-induced pro-inflammatory cytokine transcription. a, Bodipy-labeled LPS, Alexa 647-labeled CpG 1826 or
HDL were run over an S200 size exclusion column separately (a, upper panel) or together (a, lower panel) and absorbance
profiles examined. b, LPS (200 ng/ml), CpG (100 nM) or P3C (50 ng/ml) were incubated with HDL (2 mg/ml), and BMDMs
stimulated for 30 min. Whole cell lysates were analyzed for p38 phosphorylation (p-p38) relative to total β-actin. c,d BMDMs
were pre-treated with HDL (2 mg/ml) for 6 h before stimulation with CpG (100 nM) for indicated times: total cellular
cholesterol (c) and phosphorylation of p38, JNK, NF-κB p65 and IκBα degradation (d). e,f BMDMs were pre-treated with HDL
as before, and stimulated with CpG (100 nM) for 30 min: subcellular localization of NF-κB p65 (β-tubulin: cytoplasmic loading
control; poly ADP ribose polymerase (PARP): nuclear loading control) (e) and NF-κB binding to a target probe as analysed by
EMSA (f). g,h BMDMs were pre-treated with HDL as before: CpG-induced phospho-NF-κB p65 and intracellular IL-6 and
IL-1β were measured in whole cell extracts, (g); secreted IL-6 measured by ELISA (h). mRNA expression of BMDMs pre-
treated with HDL as before, and stimulated with 100 nM CpG for 4 h (i). j, Liver mRNA profile 1 h after C57BL/6 mice were
injected with CpG following 6 h HDL pre-treatment (n=8). a, Data is representative of at least three independent experiments. b,
Representative immunoblot and densitometric analysis combined from three independent experiments (mean ±S.E.M, each
ligand; no HDL versus HDL incubation ***p<0.005). c–i, Representative data from at least three independent experiments
(mean ±S.D). j, Mean values ±S.E.M, CpG versus HDL+CpG *p<0.05.
De Nardo et al. Page 21
Nat Immunol. Author manuscript; available in PMC 2014 August 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 3.
Microarray analysis identifies ATF3 as a candidate gene for the anti-inflammatory function of HDL. a, Immortalized-BMDMs
were pre-treated with HDL (2 mg/ml) for indicated times, then either washed twice in serum-free DMEM, or left unwashed,
before overnight stimulation with CpG (100 nM). TNF secretion was measured by ELISA and normalized to CpG treatment
alone. b, BMDMs were pre-treated with HDL (2 mg/ml) for 12 h, then either washed twice in serum-free DMEM, or left
unwashed, before stimulation with CpG (100 nM) for indicated times. IL-6 was measured in culture supernatants and
normalized to CpG treatment alone. c–f, Microarray analysis of BMDMs pre-treated for 6 h with HDL (2 mg/ml) then
stimulated with CpG (100 nM) for 4 h. c, Venn diagram shows genes with differential expression (vs control) and the overlap in
these genes (Fold Change limit 1.8, False discovery rate p<0.05). d, A fold change/fold change plot shows directional gene
expression resulting from CpG treatment (red), CpG and HDL treatment (blue) or genes that are co-regulated in both treatments
(purple). e, Expression of transcription factors following HDL, CpG or combined treatment as described in the methods and
presented as a heat map. TFs are ranked according change in expression across treatments, while color intensity shows the mean
expression value per condition. a,b, Representative data from at least three independent experiments (mean ±S.D) c–e, At least
three biological replicates per condition were generated.
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HDL induces ATF3 expression. a,b, BMDMs were treated with HDL (2 mg/ml) for the indicated time points or LPS (200
ng/ml) for 6 h, and ATF3 mRNA expression (a) or protein (*indicates a non-specific band) relative to total β-actin was analyzed
(b) c,d, BMDMs were pre-treated with HDL (2 mg/ml) for 6 h and stimulated with CpG (100 nM) or P3C (50 ng/ml) for 4 h :
ATF3 mRNA (c) and ATF3 protein (d). e, BMDMs were treated with HDL or native HDL (2 mg/ml) or LPS for 10 h and ATF3
mRNA expression was measured by qPCR (e). f,g CD14+ monocytes were pre-treated with HDL as before, and stimulated with
P3C (1 μg/ml) for 4 h; ATF3 mRNA expression (f) or protein (g). h,i, qPCR analysis of ATF3 mRNA expression in the livers
(n=9) (h) or Kupffer cells (n=6) (i) of C57BL/6 mice 10 h after 2 mg i.p. HDL injection. a,c,e One of at least three independent
experiments shown (mean ±S.D.) b, Representative immunoblot and densitometric analysis combined from four independent
experiments (mean ±S.E.M, untreated versus HDL treated *p<0.05). d,g, Representative blot of at least two separate
experiments. f, Data is represented as the mean from four individual donors (one-tailed student t test, untreated versus HDL
treated *p<0.05) h,i Data are shown as the mean ±S.E.M, PBS versus HDL injected mice *p<0.05.
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ATF3 is active following induction by HDL. a–c, ATF3 ChIP sequencing of BMDMs pre-treated with HDL (2 mg/ml) for 6 h
followed by stimulation with CpG (100 nM) for 4 h. Distribution of ATF3 binding within the genome (upper) and promoter
regions (lower panel) (a) and global ATF3 peak localization relative to transcription start site (TSS); normalized average of tags
per peak per bp from −1kb to +1kb (b). Genomic loci of Il6, Il12p40 and Tnf with ChIP-Seq signals for ATF3 binding under the
stimulation conditions, red bars indicate significant peaks (c). d,e qPCR analysis of ATF3, IL-6, IL-12p40 or Ch25h mRNA
expression in livers from Apoe-deficient mice fed on a high fat diet diet and injected intravenously (i.v.) with PBS or HDL (100
mg/kg) (n=5). a–c, At least three biological replicates per condition were generated. d,e Data are shown as the mean ±S.E.M,
PBS versus HDL **p<0.01, ***p<0.001.
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ATF3 mediates much of the transcriptional response to HDL treatment of macrophages. a–b, Microarray and ChIP-Seq analysis
of WT and Atf3-deficient BMDMs pre-treated with HDL (2 mg/ml) for 6 h and subsequently stimulated for 4 h with CpG (100
nM) or P3C (50 ng/ml). a Schematic representation of the model used to identify ATF3 target genes (also see Methods). b
Visualization of transcripts induced (left panel) or repressed (right panel) by CpG. At least three biological replicates per
condition were generated.
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ATF3 is required for the anti-inflammatory effect of HDL in vitro and in vivo. a, ELISA from WT or Atf3-deficient BMDMs
pre-treated with HDL (2 mg/ml) for 6 h prior to overnight stimulation with CpG (indicated doses). b, WT or Atf3-deficient mice
injected i.p with HDL (2 mg) 6 h before subsequent injection with CpG (30 μg) and D-gal (10 mg) for a further 10 h. Serum
ALT, serum TNF and hepatic TNF (WT n=10, Atf3−/− n=8,), and serum IL-12p40 (n=6) were measured. c,d, HDL increased
re-endothelialization after carotid artery injury in WT, but not Atf3-deficient mice. Carotid injury was performed on WT or Atf3-
deficient mice, 3 h later PBS or HDL (20 mg/kg) was injected i.v. Re-endothelialization was evaluated 3 days following carotid
injury (WT PBS n=8, WT HDL n=7, Atf3−/− PBS n=7, Atf3−/− HDL n=9). e Gene set enrichment analysis using the
macrophage/carotid injury overlapping gene set applied to the carotid injury dataset assessing gene enrichment in HDL treated
samples derived from WT versus Atf3−/− mice. a, Combined data from three independent experiments are shown as the mean
±S.E.M (WT versus Atf3−/− *p<0.05, **p<0.01). b, Data are presented as mean values ±S.E.M, CpG versus HDL+CpG (per
genotype) *p<0.05, ***p<0.001. c, Data are presented as mean values ±S.E.M, PBS vs HDL (per genotype) **p<0.01. d,
Images are representative of each group in each genotype. e, At least three biological replicates per condition were generated.
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